Parker Charles Nolan 4

What Happened Parker Charles Nolan, Chief Financial Officer of Traws Pharma, was granted a derivative award of options covering 90,000 shares on July 9, 2026. The Form 4 reports the grant as an acquisition of a derivative interest at $0.00 (reporting convention); no common shares were purchased or sold and no cash changed hands at grant.

Key Details

• Transaction date: 2026-07-09; Form 4 filed: 2026-07-14 (filed 5 days after the transaction; later than the typical 2-business-day filing deadline).
• Transaction type: A (Award/Grant of stock options); reported acquisition amount: $0.00; total reported value: $0 (derivative).
• Vesting: The award vests 100% on the first anniversary of the grant date (per footnote).
• Plan/approval: Options awarded under the Issuer’s 2021 Incentive Compensation Plan, as amended; granted by the issuer’s compensation committee comprised of independent directors.
• Shares owned after transaction: Not disclosed in the filing.

Context This was an options grant (a compensation award), not an open-market purchase or sale. The grant gives Nolan the right to acquire shares in the future subject to vesting and the plan’s terms; it does not indicate immediate sale or exercise. Retail investors typically view awards as routine executive compensation; they are informative about company retention and incentive practices but do not by themselves signal a buy or sell decision.